Últimas noticias sobre Gain Therapeutics (NASDAQ:GANX) Bolsa

Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

SILO

Descubre las últimas transacciones de insiders en penny stocks como ALZN, GANX, AZTR y SILO. ¡Aprovecha esta información privilegiada ahora!

Compras de insiders de penny stocks: ALZN, GANX, AZTR, SILO

Gain Therapeutics Inc

LXEH

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

CNET

SONN

<p>High Tide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>), a retail-driven cannabis company, announced Friday that it placed No. 87 out of 417 companies listed on the 2024 Report on Business ranking of Canada's Top Growing Companies. </p>
<p>High Tide achieved an impressive three-year revenue growth rate of 486%. This consistent growth earned the company a place in the index for the 4th year in a row.</p>
<h3 class="wp-block-heading"><strong>Consistent Growth In A Competitive Market</strong></h3>
<p>High Tide&#8217;s ranking in 2024 follows its 2023 achievement, where it placed 38th with a remarkable growth rate of 1,040%. </p>
<p>This consistent upward trajectory can be attributed to the company&#8217;s<a href="https://www.benzinga.com/markets/cannabis/24/08/40245394/high-tides-cabana-club-loyalty-program-surpasses-1-5m-members-in-canada"> strong retail strategy</a> and operational success. CEO <strong>Raj Grover</strong> highlighted the success. &#8220;Our aggressive top-line growth is being translated into free cash flow generation.&#8221;</p>
<ul>
<li><strong><em>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</em></strong></li>
</ul>
<p>This growth allowed High Tide to expand its retail presence, <strong>capturing 12% of the market share in five Canadian provinces</strong>.</p>
<p>High Tide's annualized run rate now exceeds $525 million, with net income reaching $0.8 million in <a href="https://www.benzinga.com/markets/cannabis/24/09/40887415/cannabis-retailer-high-tide-reports-q3-results">the last quarter</a>. </p>
<p>In addition to dominating the <a href="https://www.benzinga.com/markets/cannabis/24/08/40558227/cannabis-sales-in-canada-decline-sharply-whats-behind-the-drop">Canadian market</a>, High Tide is looking to expand internationally. The company has set its sights on emerging cannabis markets in <a href="https://www.benzinga.com/markets/cannabis/24/08/40520655/25-german-cities-join-cannabis-pilot-trials-in-2024-under-new-legalization-law">Germany</a> and the United States.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40820402/canadas-largest-cannabis-retailer-high-tide-partners-to-bring-marijuana-offerings-to-events">Canada&#8217;s Largest Cannabis Retailer High Tide Partners To Bring Marijuana Offerings To Events</a></strong></p>
<h3 class="wp-block-heading">About The Ranking</h3>
<p>The full list of the 2024 winners of Canada's Top Growing Companies is featured in the October issue of Report on Business magazine, along with detailed editorial coverage.</p>
<p>This ranking recognizes the achievements of 417 businesses that qualified by completing a thorough application process and meeting specific revenue requirements. </p>
<p>Launched in 2019, the program celebrates Canada's most forward-thinking and fast-growing companies across various sectors.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40838052/cannabis-retail-giant-high-tide-ramps-up-offering-for-millions-of-customers">Cannabis Retail Giant High Tide Ramps Up Offering For Millions Of Customers</a></strong></li>
</ul>
<p><em>Cover Image: Courtesy of High Tide Inc.</em></p>


Cannabis

Retail Sales

Economics

HITI

High Tide Cannabis Co. Ranks Among Top Growing Businesses In Canada In 2024

<p>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 15 years by 3.4% on an annualized basis producing an average annual return of 15.43%. Currently, Humana has a market capitalization of $38.48 billion. </p>
<p><strong>Buying $1000 In HUM:</strong> If an investor had bought $1000 of HUM stock 15 years ago, it would be worth <strong>$8,712.38</strong> today based on a price of $319.57 for HUM at the time of writing.</p>
<h3>Humana's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727472623_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 15 Years Ago Would Be Worth $8,700 Today

<p>Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 10 years by 3.22% on an annualized basis producing an average annual return of 14.6%. Currently, Ameriprise Finl has a market capitalization of $46.11 billion. </p>
<p><strong>Buying $1000 In AMP:</strong> If an investor had bought $1000 of AMP stock 10 years ago, it would be worth <strong>$3,916.59</strong> today based on a price of $468.62 for AMP at the time of writing.</p>
<h3>Ameriprise Finl's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727472618_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Ameriprise Finl 10 Years Ago Would Be Worth This Much Today

<p>Across the recent three months, 12 analysts have shared their insights on Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $746.92, with a high estimate of $795.00 and a low estimate of $600.00. This current average has increased by 2.51% from the previous average price target of $728.64. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727470860_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Intuit among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$768.00</td>
<td>$768.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$740.00</td>
<td>$745.00</td>
</tr>
<tr>
<td>Sterling Auty</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$600.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$790.00</td>
<td>$770.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$795.00</td>
<td>$690.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$760.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$780.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$768.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$757.00</td>
<td>$757.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$685.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$760.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$760.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intuit. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intuit compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Intuit's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INTU/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intuit analyst ratings.</strong></a></p>
<h2>About Intuit</h2>
<p>Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.</p>
<h3>Understanding the Numbers: Intuit's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Intuit's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately <strong>17.4%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Intuit's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-0.63%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Intuit's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.11%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Intuit's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.06%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.36</strong>, Intuit adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

INTU

Deep Dive Into Intuit Stock: Analyst Perspectives (12 Ratings)

<p>10 analysts have expressed a variety of opinions on Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Impinj, revealing an average target of $200.0, a high estimate of $225.00, and a low estimate of $175.00. This upward trend is evident, with the current average reflecting a 15.61% increase from the previous average price target of $173.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727470834_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Impinj. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Scott Searle</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$205.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$215.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Impinj. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Impinj compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Impinj's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Impinj's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Impinj analyst ratings.</strong></a></p>
<h2>Discovering Impinj: A Closer Look</h2>
<p>Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.</p>
<h3>Understanding the Numbers: Impinj's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Impinj's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>19.2%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.72%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Impinj's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.82%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Impinj's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.32%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Impinj's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.51</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Impinj: Insights From 10 Financial Analysts

<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 12.36% on an annualized basis producing an average annual return of 23.75%. Currently, IDEXX Laboratories has a market capitalization of $42.12 billion. </p>
<p><strong>Buying $100 In IDXX:</strong> If an investor had bought $100 of IDXX stock 10 years ago, it would be worth <strong>$846.20</strong> today based on a price of $511.78 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727470822_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


IDXX

Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years

<p>Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 15 years by 5.92% on an annualized basis producing an average annual return of 17.95%. Currently, Eaton Corp has a market capitalization of $130.76 billion. </p>
<p><strong>Buying $100 In ETN:</strong> If an investor had bought $100 of ETN stock 15 years ago, it would be worth <strong>$1,215.13</strong> today based on a price of $328.45 for ETN at the time of writing.</p>
<h3>Eaton Corp's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727470817_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today

<p><strong>AbbVie's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 8.18% since its last report. The company recently reported that it has <strong>17.79 million shares sold short</strong>, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.9 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727469922_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.98%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

ABBV

(ABBV) - Analyzing AbbVie's Short Interest

<p><strong>Domino's Pizza's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) short percent of float has risen 18.23% since its last report. The company recently reported that it has <strong>2.19 million shares sold short</strong>, which is 7.07% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.15 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Domino's Pizza Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727469917_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Domino's Pizza has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Domino's Pizza's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Domino's Pizza's peer group average for short interest as a percentage of float is 10.91%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Domino's Pizza's Recent Short Interest

<p><strong>Keurig Dr Pepper's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NYSE">KDP</a>) short percent of float has fallen 5.53% since its last report. The company recently reported that it has <strong>21.72 million shares sold short</strong>, which is 2.05% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.68 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Keurig Dr Pepper Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727469911_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Keurig Dr Pepper has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Keurig Dr Pepper's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Keurig Dr Pepper's peer group average for short interest as a percentage of float is 7.16%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into Keurig Dr Pepper's Recent Short Interest

<p><strong>Deere &amp; Company </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/de#NYSE">DE</a>) has recalled about 147,900 compact utility tractors in the United States due to a potential brake failure risk, per reports. This voluntary recall will ensure customer safety.</p>
<p>The recall applies to models 1023E, 1025R and 2025R sold between November 2017 and July 2024. In Canada, the company has recalled another 16,800 of the compact utility tractor models.</p>
<p>The front bell crank in the brake linkage of the recalled tractors may break, endangering users in the event of a crash, according to the Consumer Product Safety Commission (&quot;CPSC&quot;). There have been four reports of brake linkage failure in the United States so far, with one hospitalization, two impact injuries and minor damages to the tractors.</p>
<h2>Deere&#39;s Commitment to Safety</h2>
<p>The company is proactively addressing the issue in collaboration with the U.S. CPSC.</p>
<p>Deere instructed the impacted customers not to operate their tractors until they receive a free repair from an authorized Deere dealer. Customers have easy access to repair services due to over 2,000 dealerships in the United States and Canada. If the consumer is unable to move the tractor to a dealer&#39;s site, the company will arrange to repair the unit at the consumer&#39;s home.</p>
<h2>DE&#39;s Topline Dips Y/Y in Q3</h2>
<p>Deere reported third-quarter fiscal 2024 earnings of $6.29 per share, which beat the Zacks Consensus Estimate of $5.80. The bottom line, however, plunged 38% from the prior-year quarter.</p>
<p>This was due to lower shipment volumes across all segments, reflecting weak demand, which was somewhat negated by the company&#39;s pricing strategies and cost-saving measures.</p>
<p>Net sales of equipment operations (comprising Agriculture, and Turf, Construction and Forestry) were $11.39 billion, down 19.9% year over year. However, net sales topped the Zacks Consensus Estimate of $10.87 billion. Total net sales (including financial services and others) were $13.15 billion, down 16.8% year over year.</p>
<h2>Deere&#39;s 2024 Net Income Outlook Indicates Y/Y Dip</h2>
<p>Deere stated that in the wake of challenging conditions in the global agricultural and construction sectors, the company will align its production with demand levels and also take steps to reduce costs. Deere maintained its guidance of net income for fiscal 2024 at $7 billion. The view suggests a 31% decline from net income of $10.2 billion reported in fiscal 2023.</p>
<p>Net sales for Production &amp; Precision Agriculture are expected to decrease 20-25% year over year in fiscal 2024. Sales of Small Agriculture &amp; Turf are expected to dip 20-25%. Deere projects sales of Construction &amp; Forestry to be down 10-15%. The Financial Services segment&#39;s net income is expected to be $720 million.</p>
<h2>DE Share Price Outperforms Industry</h2>
<p>DE shares have gained 8.7% in the past year compared with the industry&#39;s growth of 4%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/1c/79542.jpg?v=1652687335" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>Deere&#39;s Zacks Rank &amp; Stocks to Consider</h2>
<p>DE currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks from the Industrial Products sector are <strong>Crane Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cr#NYSE">CR</a>), <strong>Flowserve Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fls#NYSE">FLS</a>) and <strong>RBC Bearings Incorporated</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbc#NYSE">RBC</a>). Each stock presently carries a Zacks Rank #2 (Buy).</p>
<p>The Zacks Consensus Estimate for Crane&#39;s 2024 earnings is pegged at $5.07 per share. The consensus estimate for 2024 earnings has moved north by 6% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 11.2%. CR shares have gained 75.2% in a year.</p>
<p>Flowserve has an average trailing four-quarter earnings surprise of 18.2%. The Zacks Consensus Estimate for FLS&#39; 2024 earnings is pinned at $2.76 per share, which indicates year-over-year growth of 31.6%. The consensus estimate for 2024 earnings has moved north by 4% in the past 60 days. The company&#39;s shares have gained 27.5% in a year.</p>
<p>The Zacks Consensus Estimate for RBC Bearings&#39; fiscal 2025 earnings is pegged at $9.71 per share. The consensus estimate for 2025 earnings has moved north by 1.4% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 4.7%. RBC shares have gained 27.2% in a year.</p>
<p><a href="https://www.zacks.com/stock/news/2342803/deere-recalls-its-compact-utility-tractors-for-brake-failure-risk?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2342803">To read this article on Zacks.com click here.</a></p>


Earnings

Large Cap

Guidance

Deere Recalls Its Compact Utility Tractors for Brake Failure Risk

<p>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock has remained below $1.00 per share through the initial 180-day compliance period ended September 23, 2024. The Company is not eligible for a second 180-day period because it does not comply with the minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The Nasdaq Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing on The Nasdaq Capital Market at an upcoming hearing which will also consider the Company's non-compliance with the $2.5 million stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1).</p>


ENSC

Ensysce Biosciences Receives Notice from Nasdaq; The Company Is Not Eligible For A Second 180-Day Period Because It Does Not Comply With The Minimum Stockholders' Equity Requirement For Initial Listing On The Nasdaq Capital Market

General

Global Mofy AI Limited Announces Receipt Of Notification From Nasdaq Due To Closing Bid Price Requirement

<p><strong>AECOM </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acm#NYSE">ACM</a>) won a contract from the Los Angeles County Metropolitan Transportation Authority (Metro) to provide program management, design and engineering services.</p>
<p>Banking on its Sustainable Legacies strategy, ACM will support Metro&#39;s ambitious goal of transitioning its bus fleet to Zero Emission Buses. Also, it will focus on charging infrastructure conceptual design, specification, and procurement. Its expertise will help guide the seamless transition to zero-emission operations, offering innovative solutions to complex transportation challenges.</p>
<p>The sustainable and efficient transit system aims to reduce greenhouse gas emissions while improving air quality for Los Angeles County residents. On an impressive note, the initiative is one of the largest electric bus programs in the United States and is supported by the Infrastructure Investment and Jobs Act.</p>
<h2>ACM&#39;s Stock Performance</h2>
<p>The company&#39;s shares have gained 11.6% so far this year, which is nearly one-third of the Zacks Engineering - R and D Services industry&#39;s 36.2% growth.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/db/79473.jpg?v=371988059" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>This Zacks Rank #4 (Sell) company has been ailing from labor shortages, particularly in skilled trades. Inflationary pressures, particularly in raw materials and energy, could also be bothering margins. This apart, broader economic uncertainties, such as fears of a recession or global economic slowdown, might be impacting the infrastructure sector. Investors could be cautious about long-term infrastructure spending, especially if government funding slows down.</p>
<h2>ACM&#39;s Strong Backlog &amp; Global Demand Drive Raises Hope</h2>
<p>Mitigating the above-mentioned headwinds, AECOM has been experiencing robust growth across all its segments, backed by strong pipeline visibility for the upcoming quarters. Healthy state and local budgets, along with increased private sector investments in water and energy transitions, have contributed to this upward trend.</p>
<p>Additionally, the U.K. water market is expected to see accelerated growth over the next five years, driven by a near doubling of AMP8 funding. AECOM&#39;s deep expertise with major water utilities positions it well to benefit from this expansion.</p>
<p>Global demand for infrastructure development is rising, further increasing the need for AECOM&#39;s services. As of the fiscal third-quarter end, the total backlog was $23.36 billion compared with $23.21 billion reported in the prior-year period. The current backlog level includes 54.8% contracted backlog growth.</p>
<p>Ongoing contract wins are expected to boost prospects. Global infrastructure spending trends remain strong, providing further opportunities for AECOM&#39;s continued expansion.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the same space are:</p>
<p><strong>Sterling Infrastructure, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) presently sports a Zacks Rank #1 (Strong Buy). Sterling Infrastructure has a trailing four-quarter earnings surprise of 17.4%, on average.</p>
<p>The Zacks Consensus Estimate for STRL&#39;s 2024 sales and earnings per share indicates a rise of 9.7% and 26.6%, respectively, from the prior-year levels.</p>
<p><strong>Howmet Aerospace Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hwm#NYSE">HWM</a>) presently carries a Zacks Rank #2 (Buy). HWM has a trailing four-quarter earnings surprise of 10.9%, on average.</p>
<p>The Zacks Consensus Estimate for HWM&#39;s 2024 sales and EPS indicates a rise of 12.6% and 40.8%, respectively, from the prior-year levels.</p>
<p><strong>M-tron Industries, Inc.</strong> (AMEX:MPTI) currently carries a Zacks Rank #2. It has topped earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 9.2%.</p>
<p>The Zacks Consensus Estimate for MPTI&#39;s 2024 sales and EPS indicates a rise of 16.1% and 76.6%, respectively, from prior-year levels.</p>
<p><a href="https://www.zacks.com/stock/news/2342821/aecom-wins-contract-to-support-la-metro-s-zeb-transition?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2342821">To read this article on Zacks.com click here.</a></p>


Mid Cap

Contracts

Small Cap

MPTI

STRL

AECOM Wins Contract to Support LA Metro's ZEB Transition

Management

Icahn Enterprises Says Ted Papapostolou To Continue To Serve As CFO Of Co And Certain Of Its Units, For Term Through June 30, 2028

<p><em>45 percent reduction in risk of death achieved with CARVYKTI&reg; after three-year follow-up in landmark CARTITUDE-4 study&nbsp;</em></p>
<p><em>Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting</em></p>
<p>RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI&reg; (ciltacabtagene autoleucel)&nbsp;significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 With these data, CARVYKTI&reg; is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1&nbsp;Findings were featured as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65).1</p>


Biotech

LEGN

Johnson & Johnson And  Legend Biotech Corp Announce CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After Three-year Follow-up In Landmark CARTITUDE-4 Study

<p>Financial giants have made a conspicuous bullish move on Marriott Intl. Our analysis of options history for Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 55% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $760,957, and 5 were calls, valued at $169,571.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $150.0 and $300.0 for Marriott Intl, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Marriott Intl options trades today is 83.57 with a total volume of 3,515.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Marriott Intl's big money trades within a strike price range of $150.0 to $300.0 over the last 30 days.</p>
<h3>Marriott Intl Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727469191_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.0</td>
<td>$5.9</td>
<td>$5.9</td>
<td>$240.00</td>
<td>$338.1K</td>
<td style="text-align: right;">226</td>
<td>663</td>
</tr>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.1</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$240.00</td>
<td>$308.0K</td>
<td style="text-align: right;">226</td>
<td>1.3K</td>
</tr>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$10.9</td>
<td>$10.1</td>
<td>$10.9</td>
<td>$240.00</td>
<td>$81.7K</td>
<td style="text-align: right;">20</td>
<td>75</td>
</tr>
<tr>
<td>MAR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$110.9</td>
<td>$108.5</td>
<td>$110.9</td>
<td>$150.00</td>
<td>$55.4K</td>
<td style="text-align: right;">24</td>
<td>5</td>
</tr>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.8</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$240.00</td>
<td>$33.0K</td>
<td style="text-align: right;">226</td>
<td>1.3K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Marriott Intl</h3>
<p>Marriott operates 1.7 million rooms across roughly 30 brands. At the end of 2023, luxury represented roughly 10% of total rooms, premium 42%, select service was 46%, midscale 1%, and other 1%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 97% of total rooms as of Dec. 31, 2023. North America makes up 63% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.</p>
<p>After a thorough review of the options trading surrounding Marriott Intl, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Marriott Intl's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,235,041, the price of MAR is up by 0.93%, reaching $253.04.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 34 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Marriott Intl</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $264.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Goldman Sachs downgraded its action to Buy with a price target of $267.<br />
&#x2A; An analyst from Bernstein upgraded its action to Outperform with a price target of $262. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Marriott Intl with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Decoding Marriott Intl's Options Activity: What's the Big Picture?

Gain Therapeutics, Inc. (GANX) Special Call Transcript

The latest update is out from Gain Therapeutics (GANX). Gain Therapeutics, Inc. has successfully completed the multiple ascending dose phase of its...

Gain Therapeutics Advances Parkinson's Treatment in Phase 1

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hims & Hers Health (HIMS – Research Report) and Gain...

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and Gain Therapeutics (GANX)

Maxim Group analyst Jason McCarthy has maintained their bullish stance on GANX stock, giving a Buy rating today. Jason McCarthy's rating is based o...

Optimistic Outlook for Gain Therapeutics Amid Progress of GT-02287 and Successful Financing

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are not for everyone, let&rsquo;s make that perfectly clear. It&rsquo;s challenging to invest in a field in which companies &ndash; particularly startups &ndash; can go for years without seeing a penny of revenue. </p>



<p>While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get in too much trouble.</p>



<p>Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and technologies, working in the fields of gene therapy, personalized medicine and biologics.</p>



<p>The challenge in this sector is that it takes a long time to bring a new drug or therapy to market. </p>



<p>Even after the drug or therapy is discovered and developed in a laboratory setting, biotech companies must undergo preclinical research and a series of clinical trials. All these trials  must be successful to go to the next step in the process. </p>



<p>Clinical trials can often be expensive and time-consuming. And if the drug or therapy passes all of that, it still needs to get approval from the Food and Drug Administration (and regulators in other countries) before it can be brought to market.</p>



<p>Well-established biotech companies that have a history of success can better withstand these issues if they&rsquo;ve previously brought drugs to market and are bringing in revenue. </p>



<p>But for a new company that doesn&rsquo;t have a revenue stream, clinical trials can try the patience of any investor &ndash; particularly as a company goes deeper into debt.</p>



<p>The biotech stocks we&rsquo;re looking at today all have good ideas, but the hurdles they have to clear to turn the corner are extremely high. </p>



<p>If you&rsquo;re going to invest in the biotech sector, you should consider avoiding these names &ndash; and if you&rsquo;re an investor, you should take this opportunity to recognize biotech stocks to sell now.</p>



<h2>Ginkgo Bioworks (DNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/dna_ginkobioworks1600-300x169.png" alt="Person holding mobile phone with logo of American biotechnology company Ginkgo Bioworks Inc. on screen in front of web page. Focus on phone display. Unmodified photo. DNA stock"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Ginkgo Bioworks</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dna-stock-quote/"><strong>DNA</strong></a>) is a Boston-based company that uses genetic engineering to produce bacteria with industrial applications for other biotech companies.</p>



<p>The company specializes in cell programming and biosecurity. It&rsquo;s <a href="https://finance.yahoo.com/news/ginkgo-bioworks-novo-nordisk-expand-110200616.html">working</a> with Dutch biotech company <strong>Novo Nordisk</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/"><strong>NVO</strong></a>) on several research and development projects over the next five years, including diabetes and obesity medications.</p>



<p>Ginkgo also <a href="https://www.syngenta.com/en/company/media/syngenta-news/year/2024/syngenta-collaborates-ginkgo-bioworks-enable-faster-launch">announced</a> a collaboration with agricultural company Syngenta to develop and optimize a microbial strain for a secondary metabolite in Syngenta&rsquo;s pipeline.</p>



<p>As promising as these sound, the reality doesn&rsquo;t match up. DNA stock is down 82% this year and the company has just been trying to maintain its New York Stock Exchange <a href="http://investors.ginkgobioworks.com/news/news-details/2024/Ginkgo-Bioworks-Receives-Continued-Listing-Standard-Notice-From-NYSE/default.aspx">listing compliance</a>.</p>



<p>The company also instituted deep staff cuts, <a href="https://investorplace.com/2024/06/ginkgo-bioworks-layoffs-expand-to-400-job-cuts/">laying off</a> at least 35% of its 1,200-member workforce. &nbsp;</p>



<p>Revenue in the first quarter was $38 million, down from $81 million in the first quarter of 2023. Overall, the company reported a loss of $178 million for the quarter.</p>



<p>DNA stock gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Tonix Pharmaceuticals (TNXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div><p><strong>Tonix</strong> <strong>Pharmaceuticals </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/txnp-stock-quote/"><strong>TXNP</strong></a></span>) is making drugs and therapies to treat central nervous system disorders. But like many other biotech companies, it&rsquo;s paying the bills is a challenge.</p>



<p>Tonix hasn&rsquo;t yet brought a drug to market. It does have a candidate in Phase 3 testing as a treatment for fibromyalgia. The company is hoping for FDA approval for its drug, Tonmya, in the second half 2025.</p>



<p>Tonix also has a therapy in Phase 2 trials that would treat long Covid-19 symptoms, but Tonmya is much closer to becoming a reality.</p>



<p>That&rsquo;s why the company&rsquo;s trying to raise money. It had&nbsp;<a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1490/tonix-pharmaceuticals-announces-closing-of-4-0-million">two separate $4 million public offerings in June</a>&nbsp;that will help, but also served to dilute investor equity. It also completed a 1-for-32 reverse stock split to regain Nasdaq listing compliance.</p>



<p>Tonix recorded a <a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1469/tonix-pharmaceuticals-reports-first-quarter-2024-financial">net loss of $14.9 million in the first quarter,</a>&nbsp;or 18 cents per share. It only had $7 million in cash on hand at the end of the quarter, so it needs all the money it can get from its fundraising efforts.</p>



<p>TNXP stock is already back below $1 per share, having dropped 93% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<p>Tonix stock is down 95% this year, getting an &ldquo;F&rsquo; rating in the Portfolio Grader.</p>



<h2>Gain Therapeutics (GANX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div><p><strong>Gain Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ganx-stock-quote/"><strong>GANX</strong></a>) is a Maryland company that is developing possible therapies for neurodegenerative diseases, genetic disorders and cancer. </p>



<p>The company lead candidate, which is in Phase 1 trials, has the potential to treat Parkinson&rsquo;s disease and other neurodegenerative diseases such as Gaucher disease, and Alzheimer&rsquo;s disease.</p>



<p>Gain also has a drug discovery platform called Magellan that uses artificial intelligence to help it develop therapies.</p>



<p>It&rsquo;s also trying to raise money, although doing so isn&rsquo;t a good deal for current shareholders. </p>



<p><a href="https://investorplace.com/2024/06/why-is-gain-therapeutics-ganx-stock-down-25-today/">Last month</a> it sold 7.11 million shares at $1.35 each in an effort to raise $11 million so it can continue testing its lead drug candidate. But the public offering also increased the number of shares in the company, which diluted shares.</p>



<p>It&rsquo;s also notable that CEO Matthias Alder abruptly left Gain in late June. He was replaced on an interim basis by Gene Mack, the chief financial officer.</p>



<p>All in all, Gain appears not to be on firm footing and is a long way from seeing revenue from its top drug candidate. The stock is down 62% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.</p>



<h2>GlycoMimetics (GLYC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div><p><strong>GlycoMimetics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/"><strong>GLYC</strong></a>) is another Maryland company. It&rsquo;s working on developing glycobiology-based therapies for cancer and inflammatory disease.</p>



<p>Glycobiology involves working with carbohydrates or sugar chains in an effort to develop appropriate therapies.</p>



<p>But the company took a major hit this spring when Phase 3 trials of its lead drug candidate failed to be statistically significant. The drug, uproleselan, was bring developed for the treatment of relapsed/refractory acute myeloid leukemia.</p>



<p>The company <a href="https://www.nasdaq.com/press-release/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsed">noted</a> that the study didn&rsquo;t &ldquo;achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.&rdquo; </p>



<p>Patient survival reached a median of 13 months as compared to 12.3 months just with chemotherapy.</p>



<p>The company said it&rsquo;s planning to meet with regulators and the National Cancer Institute to determine a path forward. Meanwhile, the floor has fallen out from GLYC stock, which is down 87% on the year. It gets a &ldquo;D&rdquo; rating in the Portfolio Grader.</p>



<h2>GRI Bio (GRI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>GRI Bio</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/"><strong>GRI</strong></a>) is developing therapies to treat inflammatory disease. </p>



<p>Its&nbsp;therapies would target the activity of Natural Killer T (&ldquo;NKT&rdquo;) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression.</p>



<p>The company has four drug candidates in its pipeline, with the most advanced being a treatment for idiopathic pulmonary fibrosis. That candidate is in Phase 2 trials.</p>



<p>Like many other early-stage biotech companies, GRI Bio is trying to raise money to keep the doors open, while at the same time <a href="https://gribio.com/gri-bio-regains-compliance-with-nasdaq/">trying not to be delisted by the index</a>.</p>



<p>The company announced late last month that it would sell more than 2 million shares of GRI stock &ndash; an <a href="https://investorplace.com/2024/06/why-is-gri-bio-gri-stock-down-29-today/">announcement</a> that sent the stock price down by 29%.</p>



<p>GRI stock is now down 95% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.</p>



<h2>Ovid Therapeutics (OVID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Ovid Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ovid-stock-quote/"><strong>OVID</strong></a>) is a biotech company that is working to create therapies to combat neurological diseases. </p>



<p>Its drug candidate to treat brainstem malformations completed Phase 1 trials, while three other drug candidates are not as far advanced.</p>



<p>Ovid also has a partnership with Takeda to bring another drug, soticlestat to market to treat Dravet syndrome and Lennox-Gastaut syndrome. </p>



<p>Both therapies are in Phase 3 trials, but the top-line study results are not promising. </p>



<p>The treatment for Dravet syndrome narrowly missed its primary endpoint in reducing the frequency of seizures, and its treatment for Lennox-Gastaut syndrome missed its mark in reducing motor drop seizures.</p>



<p>Ovid only had revenue of <a href="https://investors.ovidrx.com/news/news-details/2024/Ovid-Therapeutics-Reports-Business-Updates-and-First-Quarter-2024-Financial-Results/default.aspx">$148,000 in the first quarter</a> versus operating expenses of $17.2 million. The company has roughly $90 million of cash on hand, so it&rsquo;s not at immediate risk. But it&rsquo;s also a long way from turning a profit as well.</p>



<p>OVID stock is down 70% this year &ndash; with much of that drop coming after the Phase 3 trials on soticlestat were released. and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.</p>



<h2>Cosmos Health (<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/"><strong>COSM</strong></a>)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Cosmos Health</strong> (NASDASQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/"><strong>COSM</strong></a>) is a Chicago company that serves as a holding company. </p>



<p>Its portfolio includes pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept.</p>



<p>The company also operates a subsidiary, Cana Laboratories, to manufacture pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. </p>



<p>The company makes and sells branded generics and over-the-counter medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the U.K.</p>



<p>The company has not yet filed its fourth-quarter report, and received a notice of noncompliance from Nasdaq for the failure. </p>



<p>But its third-quarter report included a couple of red flags, including a drop in year-to-date revenue from $38.3 million to $37.5 million; and a drop in cash from $20.7 million to $2.3 million.</p>



<p>COSM stock is down 10% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.</p>



<p><em>On the date of publication, Louis Navellier had a long position in NVO. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article.</em></p>



<p><em>InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/market360/2024/07/7-sorry-biotech-stocks-set-to-make-investors-sad-2/">7 Sorry Biotech Stocks Set to Make Investors Sad</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Sorry Biotech Stocks Set to Make Investors Sad

Gain Therapeutics GAAP EPS of -$0.42

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Gain Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ganx-stock-quote/"><strong>GANX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Gain Therapeutics reported earnings per share of -42 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ganx-stock-earnings-gain-therapeutics-for-q2-of-2024/">GANX Stock Earnings: Gain Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

GANX Stock Earnings: Gain Therapeutics Misses EPS for Q2 2024

Gain slips after early-stage data for Parkinson's therapy

Gain Therapeutics (GANX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

Buy Rating Affirmed for Gain Therapeutics on Promising Phase 1 Results and Solid Financial Outlook

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price target at $5.00...

Optimistic Buy Rating for Gain Therapeutics' GT-02287 Based on Promising Parkinson's Disease Treatment Potential

COSM

GLYC

HIMS

OVID

Health Care

Press Releases

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Comments

Gain Therapeutics

Noticias

Últimas noticias sobre Gain Therapeutics (NASDAQ:GANX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL